---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-073496"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2026-06-12T20:23:11+00:00"
generated_at: "2026-06-12T20:42:48.401273+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix appoints Jason Robins as permanent CFO; shareholders approve 10M share increase to stock plan

## Summary
- Jason Robins, interim CFO since Jan 2026, appointed permanent CFO; salary raised to $535,100 effective July 1, 2026, plus stock option and RSU grants.
- Shareholders approved Amendment No. 5 to 2021 Stock Incentive Plan, increasing shares by 10,000,000.
- Shareholders elected Pravin U. Dugel, M.D. and Merilee Raines as Class III directors for term until 2029.
- Advisory say-on-pay vote approved (116.1M for, 40.1M against); frequency set to 'One Year' (154.2M votes for one year).
- PricewaterhouseCoopers ratified as independent auditor for FY2026 (187.2M for, 2.1M against).

## SEC filing metadata
- accession: 0001104659-26-073496
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2026-06-12T20:23:11+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/0001104659-26-073496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-073496
- JSON: https://secwatch.observer/filing/0001104659-26-073496.json
- Plain text: https://secwatch.observer/filing/0001104659-26-073496.txt

## Key facts
- Executive change
  Jason Robins was appointed as Chief Financial Officer at OCULAR THERAPEUTIX, INC.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 10, 2026, the Board appointed Jason Robins, the Company’s interim Chief Financial Officer, to serve as the Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/0001104659-26-073496-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Amendment No. 5 to increase shares under the 2021 Stock Incentive Plan by 10,000,000 shares.
  - Proposal: equity plan
  - Outcome: passed
  source text: The Company’s stockholders approved Amendment No. 5 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 10,000,000 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/0001104659-26-073496-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Election of Pravin U. Dugel, M.D. and Merilee Raines as Class III directors to serve until the 2029 Annual Meeting.
  - Proposal: director election
  - Outcome: passed
  source text: The Company’s stockholders elected Pravin U. Dugel, M.D. and Merilee Raines as Class III directors to serve until the 2029 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/0001104659-26-073496-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Non-binding advisory vote to approve the compensation of the Company's named executive officers.
  - Proposal: say on pay
  - Outcome: passed
  source text: The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2026 Proxy Statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/0001104659-26-073496-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-12-31
  source text: The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/0001104659-26-073496-index.htm
- Shareholder Votes
  OCULAR THERAPEUTIX, INC shareholders approved Non-binding advisory vote on frequency of future advisory votes to approve named executive officer compensation.
  - Proposal: say on pay frequency
  - Outcome: passed
  source text: The Company’s stockholders approved, on a non-binding, advisory basis, “One Year” for the frequency of future advisory votes to approve the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/0001104659-26-073496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.